S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NASDAQ:CRSP

CRISPR Therapeutics (CRSP) Stock Forecast, Price & News

$64.66
+0.81 (+1.27%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$62.90
$65.50
50-Day Range
$43.14
$67.77
52-Week Range
$38.94
$86.95
Volume
1.02 million shs
Average Volume
1.23 million shs
Market Capitalization
$5.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.89

CRISPR Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
15.8% Upside
$74.89 Price Target
Short Interest
Healthy
16.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of CRISPR Therapeutics in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$2.38 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.61) to ($5.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

490th out of 1,010 stocks

Biological Products, Except Diagnostic Industry

75th out of 169 stocks


CRSP stock logo

About CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Stock News Headlines

Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings (CRSP)
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 5.3%
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 5.3%
Stifel Nicolaus Remains a Hold on Crispr Therapeutics AG (CRSP)
Why Are CRISPR Therapeutics Charts Saying 'Buy'?
CRISPR Therapeutics (NASDAQ:CRSP) Upgraded at StockNews.com
See More Headlines
Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Company Calendar

Last Earnings
5/08/2023
Today
5/29/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRSP
Fax
N/A
Employees
473
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$74.89
High Stock Price Forecast
$123.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+15.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
18 Analysts

Profitability

Net Income
$-650,170,000.00
Net Margins
-516.43%
Pretax Margin
-525.28%

Debt

Sales & Book Value

Annual Sales
$100.26 million
Book Value
$23.95 per share

Miscellaneous

Free Float
75,699,000
Market Cap
$5.10 billion
Optionable
Optionable
Beta
1.71

Key Executives

  • Dr. Rodger Novak M.D. (Age 55)
    Founder, Chairman & Pres
  • Dr. Samarth  KulkarniDr. Samarth Kulkarni (Age 43)
    CEO & Director
    Comp: $1.18M
  • Dr. Lawrence Otto Klein Ph.D. (Age 40)
    Chief Operating Officer
    Comp: $675k
  • Mr. James R. KasingerMr. James R. Kasinger (Age 50)
    Gen. Counsel & Sec.
    Comp: $648.93k
  • Mr. Shaun Foy
    Founder
  • Dr. Emmanuelle Marie Charpentier
    Co-Founder & Scientific Advisory Board Member
  • Dr. Craig C. Mello Ph.D.
    Scientific Founder & Advisory Board Member
  • Dr. Chad Cowan Ph.D.
    Scientific Founder
  • Dr. Matthew Porteus M.D. (Age 56)
    Ph.D., Scientific Founder & Advisory Board Member
  • Dr. Daniel G. Anderson Ph.D.
    Scientific Founder & Advisory Board Member













CRSP Stock - Frequently Asked Questions

Should I buy or sell CRISPR Therapeutics stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 1 sell rating, 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRSP shares.
View CRSP analyst ratings
or view top-rated stocks.

What is CRISPR Therapeutics' stock price forecast for 2023?

18 Wall Street research analysts have issued twelve-month target prices for CRISPR Therapeutics' stock. Their CRSP share price forecasts range from $39.00 to $123.00. On average, they predict the company's stock price to reach $74.89 in the next year. This suggests a possible upside of 15.8% from the stock's current price.
View analysts price targets for CRSP
or view top-rated stocks among Wall Street analysts.

How have CRSP shares performed in 2023?

CRISPR Therapeutics' stock was trading at $40.65 on January 1st, 2023. Since then, CRSP stock has increased by 59.1% and is now trading at $64.66.
View the best growth stocks for 2023 here
.

Are investors shorting CRISPR Therapeutics?

CRISPR Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 12,430,000 shares, a decrease of 5.8% from the April 30th total of 13,200,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the short-interest ratio is currently 9.5 days. Approximately 16.4% of the company's shares are sold short.
View CRISPR Therapeutics' Short Interest
.

When is CRISPR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CRSP earnings forecast
.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($1.64) by $0.97. The firm earned $100 million during the quarter, compared to analyst estimates of $24.33 million. CRISPR Therapeutics had a negative net margin of 516.43% and a negative trailing twelve-month return on equity of 26.64%. CRISPR Therapeutics's revenue was up 10538.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.32) earnings per share.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (10.16%), Sumitomo Mitsui Trust Holdings Inc. (5.05%), Nikko Asset Management Americas Inc. (5.04%), BlackRock Inc. (3.55%), FMR LLC (2.71%) and State Street Corp (2.52%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho.
View institutional ownership trends
.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $64.66.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $5.10 billion and generates $100.26 million in revenue each year. The company earns $-650,170,000.00 in net income (profit) each year or ($6.72) on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

The company employs 473 workers across the globe.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com.

This page (NASDAQ:CRSP) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -